Salvage nivolumab and ipilimumab after prior anti‐PD‐1/PD‐L1 therapy in metastatic renal cell carcinoma: A meta‐analysis

Salvage nivolumab and ipilimumab after prior anti‐PD‐1/PD‐L1 therapy in metastatic renal cell carcinoma: A meta‐analysis

Abstract Background Salvage nivolumab and ipilimumab after prior anti‐PD‐1/PD‐L1 therapy is frequently used off‐label for clear cell metastatic renal cell carcinoma (mRCC). However, limited data are available to guide such therapy. We performed a meta‐analysis to characterize further the safety and...

Full description

Bibliographic Details
Main Authors: Yuanquan Yang, Sherry V. Mori, Mingjia Li, Megan Hinkley, Anish B. Parikh, Katharine A. Collier, Abdul Miah, Ming Yin
Format: Article
Language:English
Published: Wiley 2022-04-01
Series:Cancer Medicine
Subjects:
immune checkpoint inhibitor
ipilimumab
meta‐analysis
nivolumab
renal cell carcinoma
salvage treatment
Online Access:https://doi.org/10.1002/cam4.4587

Internet

https://doi.org/10.1002/cam4.4587

Similar Items